Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.

Adult Angiogenesis Inhibitors Animals Apelin Apelin Receptors Glioblastoma Humans Mice Signal Transduction / drug effects Vascular Endothelial Growth Factor A

Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 May 2019
Historique:
received: 22 03 2018
revised: 19 10 2018
accepted: 29 01 2019
pubmed: 6 2 2019
medline: 4 7 2019
entrez: 6 2 2019
Statut: ppublish

Résumé

Antiangiogenic therapy of glioblastoma (GBM) with bevacizumab, a VEGFA-blocking antibody, may accelerate tumor cell invasion and induce alternative angiogenic pathways. Here we investigate the roles of the proangiogenic apelin receptor APLNR and its cognate ligand apelin in VEGFA/VEGFR2 antiangiogenic therapy against distinct subtypes of GBM. In proneural GBM, apelin levels were downregulated by VEGFA or VEGFR2 blockade. A central role for apelin/APLNR in controlling GBM vascularization was corroborated in a serial implantation model of the angiogenic switch that occurs in human GBM. Apelin and APLNR are broadly expressed in human GBM, and knockdown or knockout of

Identifiants

DOI: 10.1158/0008-5472.CAN-18-0881 PMID: 30718358
pubmed: 30718358
pii: 0008-5472.CAN-18-0881
doi: 10.1158/0008-5472.CAN-18-0881
doi:

Substances chimiques

APLN protein, human 0
APLNR protein, human 0
Angiogenesis Inhibitors 0
Apelin 0
Apelin Receptors 0
Aplnr protein, mouse 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2298-2313

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Giorgia Mastrella (G)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Mengzhuo Hou (M)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Min Li (M)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Veit M Stoecklein (VM)

Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Nina Zdouc (N)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Marie N M Volmar (MNM)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Hrvoje Miletic (H)

Department of Biomedicine, University of Bergen, Bergen, Norway.
Department of Pathology, Haukeland University Hospital, Bergen, Norway.

Sören Reinhard (S)

Department of Pharmacy, LMU Munich, Munich, Germany.

Christel C Herold-Mende (CC)

Division of Neurosurgical Research, Department of Neurosurgery, University of Heidelberg, Germany.

Susanne Kleber (S)

Department of Molecular Neurobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0002-9164-4666

Katharina Eisenhut (K)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Gaetano Gargiulo (G)

Max Delbrück Center for Molecular Medicine, Berlin, Germany.
ORCID: 0000-0001-5414-4251

Michael Synowitz (M)

Department of Neurosurgery, University Hospital Center Schleswig Holstein, Kiel, Germany.

Angelo L Vescovi (AL)

IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Patrick N Harter (PN)

Edinger-Institute (Neurological Institute), Goethe-University Medical School, Frankfurt am Main, Germany and German Cancer Consortium (DKTK), partner site Frankfurt/Mainz; German Cancer Research Center (DKFZ), Heidelberg, Germany.

Josef M Penninger (JM)

Institute of Molecular Biotechnology, Austrian Academy of Sciences, Vienna, Austria.
ORCID: 0000-0002-8194-3777

Ernst Wagner (E)

Department of Pharmacy, LMU Munich, Munich, Germany.

Michel Mittelbronn (M)

Edinger-Institute (Neurological Institute), Goethe-University Medical School, Frankfurt am Main, Germany and German Cancer Consortium (DKTK), partner site Frankfurt/Mainz; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Luxembourg Centre of Neuropathology (LCNP), Luxembourg and NORLUX Neuro-Oncology Laboratory, Luxembourg Institute of Health (LIH), and Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Rolf Bjerkvig (R)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Dolores Hambardzumyan (D)

Department of Pediatrics and Aflac Cancer Center of Children's Health Care of Atlanta, Emory University School of Medicine, Atlanta, Georgia.

Ulrich Schüller (U)

Institute of Neuropathology and Department of Pediatric Haematology and Oncology, University Medical Center, Hamburg-Eppendorf and Research Institute Children's Cancer Center, Hamburg, Germany.

Jörg-Christian Tonn (JC)

Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Josefine Radke (J)

Department of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, German; Berlin Institute of Health (BIH), Berlin, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany, Partner Site Berlin, Berlin, Germany.
ORCID: 0000-0001-9860-2007

Rainer Glass (R)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Walter Brendel Center of Experimental Medicine, Faculty of Medicine, LMU Munich, Munich, Germany.

Roland E Kälin (RE)

Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany. roland.kaelin@med.lmu.de.
Walter Brendel Center of Experimental Medicine, Faculty of Medicine, LMU Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de l'angiogenèse › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Eucaryotes › Animaux › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Apeline › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteur de l'apeline › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Targeting APLN/APLNR Improves Antiangiogenic...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines angiogéniques › Facteurs de croissance endothéliale vasculaire › Facteur de croissance endothéliale vasculaire de type A › Targeting APLN/APLNR Improves Antiangiogenic...